Salivary Carcinoma, NOS
Back to Diseases List
Associated Genetic Biomarkers
Salivary carcinoma, NOSs most frequently harbor alterations in TP53, EWSR1, ERBB2, NOTCH1, and HRAS .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53 Nonsense, and TP53 Exon 7 Mutation are the most common alterations in salivary carcinoma, NOS .
There is 1 clinical trial for salivary carcinoma, NOS, of which 1 is open and 0 are completed or closed. Of the trial that contains salivary carcinoma, NOS as an inclusion criterion, 1 is phase 2 (1 open).
ERBB2 and HER2 are the most frequent gene inclusion criteria for salivary carcinoma, NOS clinical trials .
Nanoparticle-based paclitaxel suspension and trastuzumab are the most common interventions in salivary carcinoma, NOS clinical trials.
Significant Genes in Salivary Carcinoma, NOS
ERBB2 is altered in 11.11% of salivary carcinoma, NOS patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for salivary carcinoma, NOS, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary carcinoma, NOS as inclusion criteria, 1 is phase 2 (1 open) .
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.